| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Fresenius Medical Care AG$25.66
-0.04 (-0.16%)
C 59Pipeline Score Tools & Services · Commercial
Market Cap
13.74 B
EPS
1.92
P/E Ratio
12.3 $
Value Trade
20.47 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
513.51 K
52 Week Range
20.95 - 30.46
% held by Insiders
0 %
% held by Institutions
8.66 %
Enterprise Value
25.53 B
Total Shares
558.58 M
Short %
0.55 %
Float Shares
558.16 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Fresenius Medical Care AG
296Total events
2Upcoming
83Tier-1 (high impact)
2006 – 2026Coverage
Upcoming catalysts 2
TBD
T2Product Launch
Subscribe to view catalyst details
TBD
T1Full Results
Subscribe to view catalyst details
Event history 2
TBD
●Trial InitiationTrial
Subscribe to view catalyst details
TBD
●Enrollment UpdateTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2011-04-18 | Phoslyra (calcium acetate) | PDUFA Date | PDUFA | Approved | – | – | – |
2011-04-18 | Phoslyra (calcium acetate) | PDUFA Date | PDUFA | Approved | – | – | – |
2011-04-18 | Phoslyra (calcium acetate) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
C59
Pipeline Score $12.8B
Pipeline ValueValuation Signal
7
Drugs Scored0.9x
rNPV / MCap Top 88%
Mid Cap (rank 111 of 913)
Percentile RankFresenius Medical Care AG carries a moderate pipeline score (59/100), with $15.3B risk-adjusted pipeline value, led by PA21 in Chronic Kidney Disease Requiring Chronic Dialysis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PA21 Small molecule | Chronic Kidney Disease Requiring Chronic Dialysis | Phase 3 | NCT01464190 | 54% | $13.3B | COMPLETED | 2,004 | - | - | Apr 1, 2013 | - | Apr 1, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in FMS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
FMS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-FMS
Jul 29, 2026▼ -0.2%today
Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients
Fresenius Medical Care has launched the BEACON-US initiative to evaluate high-volume hemodiafiltration (HVHDF) in U.S. dialysis patients. The initiative aims to gather real-world evidence on clinical outcomes and patient experiences. Early data indicates that HVHDF may lead to fewer hospitalizations and improved patient experiences, aligning with international studies.
Read more →-FMS
Jul 20, 2026Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy
Fresenius Medical Care has launched TherapyWise™, a cloud-based analytics platform designed for kidney replacement therapy in acute care settings. Integrated with the NxStage® System One™ and NxView™ 4.0, it aggregates therapy data to identify trends and improve workflow. The platform aims to enhance oversight and quality of kidney replacement therapy programs.
Read more →-FMS
May 28, 2026Bad Homburg v.d. H he
Fresenius Medical Care AG announced a share buyback program set to commence on May 28, 2026, allowing for the repurchase of up to 29,341,344 shares within a total budget of EUR 1 billion over the next twelve months. The program, authorized during the General Meeting on May 21, 2026, includes provisions for the cancellation of most repurchased shares to reduce share capital. A credit institution will manage the transactions independently, adhering to regulatory guidelines. This initiative aims to enhance shareholder value and reflects the company's confidence in its market position.
Read more →-FMS
May 21, 2026Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Sven Jacobsen T +49 171 28 79 127 sven.jacobsen@freseniusmedicalcare.com Contact for Analysts and Investors Dr. D
Fresenius Medical Care held its Annual General Meeting, highlighting a strong financial performance with an organic revenue growth of 8%. Shareholders approved a dividend of EUR 1.49 per share, and the company announced the successful completion of a EUR 1 billion share buyback program. The introduction of the 5008X CAREsystem marks a significant advancement in kidney care, with full commercial launch planned for 2026. Management emphasized their commitment to sustainable value creation and adaptability in a volatile market landscape.
Read more →-FMS
May 5, 2026▼ -10.9%on this news
Christine Peters T +49 160 60 66 770 Christine.Peters@FreseniusMedicalCare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2525 Dominik.Heger@FreseniusMedicalCare.com w
Fresenius Medical Care reported strong operational performance in Q1 2026, achieving organic revenue growth and increased profitability alongside the successful rollout of the 5008X CAREsystem. Despite these advancements, the company faced a 6% revenue decline and a 14% decrease in operating income due to significant regulatory and market challenges. The FME Reignite strategy continues to foster long-term growth, while the company undertakes measures to optimize U.S. dialysis clinic operations. Management remains committed to maintaining operational stability and shareholder value.
Read more →-FMS
Apr 14, 2026Fresenius Medical Care AG Hof (Saale) ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Invitation to the Annual General Meeting We hereby invite our shareholders to the Annual General Meeting of F
Fresenius Medical Care AG has announced its Annual General Meeting scheduled for May 21, 2026, in Frankfurt. Shareholders will find available documents regarding the meeting on the company's website. The board approved the financial statements and proposed a dividend of EUR 1.49 per share, reflecting a robust distributable profit. Additionally, the company plans to renew its share buyback authorization for treasury shares over the next five years.
Read more →-FMS
Feb 24, 2026▼ -7.8%on this news
Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 dominik.heger@freseniusmedicalcare.com w
Fresenius Medical Care has filed its Annual Report on Form 20-F for the fiscal year 2025 with the SEC. The report is available on the company's website and provides complete audited financial statements. Fresenius Medical Care remains a global leader in providing products and services for patients with renal diseases, serving approximately 292,000 patients through its dialysis clinics worldwide. The release also includes warnings about potential risks that could affect future performance.
Read more →-FMS
Jan 9, 2026Fresenius Medical Care AG is continuing its share buyback program in an accelerated manner Bad Homburg
Fresenius Medical Care AG has announced the continuation of its share buyback program, initially launched in June 2025, by initiating a second tranche. The company plans to repurchase shares worth approximately EUR 415 million from January 12, 2026, to May 8, 2026, with the aim of completing the program earlier than anticipated. This strategic move follows the earlier-than-expected completion of the first tranche in December 2025, reflecting the company's strong commitment to enhancing shareholder value.
Read more →-FMS
Dec 10, 2025Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 dominik.heger@freseniusmedicalcare.com
Fresenius Medical Care has appointed Charles Hugh-Jones as the new Global Chief Medical Officer, effective January 1, 2026. He succeeds Franklin W. Maddux, who is retiring. Hugh-Jones has extensive experience in the medical field, having previously served as CEO of Volastra Therapeutics and held senior leadership roles at Allergan, Pfizer, and Sanofi. His appointment is seen as a positive step for Fresenius Medical Care as it aims to advance its leadership in kidney care and introduces innovative treatment solutions.
Read more →-FMS
Nov 17, 2025NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Press Release Media contact Christine Peters T +49 160 60 66 770 christine.peters
Fresenius Medical Care has successfully placed a bond valued at 500 million, with a maturity date in November 2030 and a coupon rate of 3.250%. The funds raised will be allocated towards general corporate purposes, including the refinancing of existing financial liabilities. The bond is part of the company's Debt Issuance Program and has been submitted for trading on the Luxembourg Stock Exchange. However, the announcement includes advisory notes on potential risks and restrictions regarding the bond's sale in certain countries.
Read more →-FMS
Sep 18, 2025Kirsten Stratton T +1 781 929 8096 kirsten.stratton@freseniusmedicalcare.com Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors D
Fresenius Medical Care has announced strategic advancements in its Value-Based Care (VBC) segment, including a significant investment and leadership changes. The company increased its ownership stake in Interwell Health, which reported a revenue growth of 23.5% in the first half of the year. Tommy P. O'Connor will take over as CEO of Interwell Health, bringing extensive leadership experience to reinforce the company's focus on improving kidney care outcomes. These developments are part of Fresenius' FME Reignite strategy aimed at enhancing care quality while reducing costs.
Read more →-FMS
Jun 17, 2025Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches within 2 years Bad Homburg
Fresenius Medical Care AG has announced a significant share buyback program with a total volume of EUR 1 billion, set to occur over two years. The buyback is scheduled to begin in the second half of 2025 and is authorized by the company's recent Annual General Meeting. The shares will primarily be redeemed, with a smaller portion potentially used for employee compensation plans. Continued action on the buyback program will depend on forthcoming resolutions from the company's governing bodies.
Read more →-FMS
Jun 4, 2025Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Emanuela Cariolagian T +1 213 706 0051 emanuela.cariolagian1@freseniusmedicalcare.com Contact for analysts and in
Fresenius Medical Care has begun the second phase of introducing its high-volume hemodiafiltration (HVHDF) therapy in the U.S. following FDA clearance of its 5008X CAREsystem. This marks a significant step in providing improved dialysis treatment for kidney disease patients. The system includes advanced features like the Clinical Data Exchange for optimized clinic workflows. A recent study showed that patients using HVHDF had a lower mortality rate compared to traditional methods, supporting the transition to this new standard of care.
Read more →-FMS
May 14, 2025Countermotions submitted by the Association of Critical Shareholders (Dachverband der Kritischen Aktion rinnen und Aktion re e.V.) for the Annual General Meeting of Fresenius Medical Care AG on
The Association of Critical Shareholders has submitted countermotions ahead of Fresenius Medical Care's Annual General Meeting, questioning the management board's actions. Key concerns include an ongoing FTC investigation into possible anti-competitive practices and a major cost-cutting program that has resulted in the sale of clinics in Latin America. Additionally, labor unrest in California has drawn attention to alleged union-busting practices by the company. These issues reflect significant challenges facing Fresenius Medical Care as it navigates corporate governance and competitive pressures.
Read more →-FMS
Apr 10, 2025Convenience Translation Fresenius Medical Care AG Hof (Saale) ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Invitation to the Annual General Meeting We hereby invite our shareholders to the Ann
Fresenius Medical Care AG has invited its shareholders to the Annual General Meeting scheduled for May 22, 2025. During the meeting, the proposed allocation of a EUR 1.44 dividend per share will be discussed, along with the approval of financial statements for the previous fiscal year. Additionally, the management plans to introduce a new authorized capital to enhance the flexibility of share issuance, which is expected to replace previous authorizations.
Read more →-FMS
Apr 8, 2025NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND
Fresenius Medical Care AG has announced the pricing and results of its tender offers for two series of outstanding notes due in 2026, totaling EUR 300,000,000. The offers are subject to specific conditions, which have now been successfully met. Investors are invited to tender their notes for cash, with details on settlement expected on 10 April 2025. The announcement includes important specifications about the notes involved, benchmark rates, and purchase yields.
Read more →-FMS
Feb 24, 2025FME Media contact Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com FME Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 dominik.heger@freseniusmedicalca
Fresenius Medical Care has entered into an acquisition agreement with Quest Diagnostics, enabling Quest to acquire select assets from FME's Spectra Laboratories. This acquisition is aimed at enhancing laboratory services tied to end-stage kidney disease and improving operational efficiencies. As part of this arrangement, Quest will introduce dialysis-related water testing capabilities, which will benefit Fresenius's dialysis clinics across the United States. The transition of services is expected to be completed by 2025, pending customary regulatory reviews.
Read more →-FMS
Dec 18, 2024Notice relating to EUR 500,000,000 1.500% Bonds 2018/2025 (XS1854532949) EUR 600,000,000 0.625% Bonds 2019/2026 (XS2084497705) EUR 500,000,000 1.250% Bonds 2019/2029 (XS2084488209) EUR 500,000,000 1.000% Bonds 2020/2026
Fresenius Medical Care AG released a notice concerning multiple bonds under its EUR 10,000,000,000 Debt Issuance program. As of 26 November 2024, the Guarantor for these bonds is no longer an obligor under the Issuer's syndicated credit facility, resulting in the automatic release of the Guarantee. All holders of the Notes are informed that they do not need to take any action to continue receiving payments of interest and principal. The document serves informational purposes and does not constitute an offer of securities for sale in the United States or other jurisdictions.
Read more →-FMS
Dec 12, 2024Convenience translation Fresenius Medical Care AG Hof ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to section 248a sentence 1 of the German Stock Corporation Act ( Aktien
Fresenius Medical Care AG has announced the termination of a legal action against its resolution to change its legal form to a stock corporation. The action, initiated by individual shareholders, was combined with related proceedings in Frankfurt. The decision came after all shareholder claims were withdrawn, allowing the company to proceed without any ongoing legal challenges. This development is expected to enhance the company's operational stability moving forward.
Read more →-FMS
Nov 5, 2024Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@freseniusmedicalcare.com w
Fresenius Medical Care reported strong financial performance in Q3 2024, with a significant increase in operating income margin and a positive turnaround in U.S. treatment growth. The company confirmed its revenue and operating income growth outlooks for the year, tightens its operating income growth forecast to the upper end of the previous range. However, the overall revenue decreased by 4% primarily due to divestitures as part of its portfolio optimization plan. The FME25 transformation program continues to exceed savings expectations.
Read more →-FMS
May 16, 2024Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609 2601 dominik.heger@freseniusmedicalcare.com w
Fresenius Medical Care held its Annual General Meeting, highlighting positive advancements in its transformation strategy and confirming ambitious growth targets for 2024. The company reported robust growth in both top and bottom lines for 2023, surpassing its expectations. Shareholders approved a 6% increase in dividends and endorsed the new management's compensation system. CEO Helen Giza emphasized the focus on disciplined execution and building momentum moving into 2024, underlining the importance of high-quality patient care.
Read more →-FMS
May 3, 20248764 Fresenius Medical Register VIF Proof 2 Annual General Meeting of Fresenius Medical Care AG Date
Fresenius Medical Care AG has announced the details regarding its upcoming Annual General Meeting, set to be held on May 16, 2024. In an effort to promote environmental sustainability, the company is reducing the amount of printed materials by providing access to documents online. Shareholders are encouraged to participate in voting on various agenda items through a proxy system, with clear instructions on how to submit their voting preferences. The meeting will address key resolutions including compensation reports and changes to the Articles of Association.
Read more →-FMS
Mar 5, 2024▲ +11.2%on this news
Christine Peters T +49 160 60 66 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Ilia K rten T +49 6172 268 59 66 ilia.kuerten@freseniusmedicalcare.com www.fre
Fresenius Medical Care announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile, and Ecuador to DaVita Inc. for USD 300 million. This is part of the company's ongoing portfolio optimization program, aimed at reducing complexity and enhancing profitability. The sales, which involve 154 clinics and over 30,000 patients, are subject to regulatory approvals and are expected to close throughout 2024. While the transactions could generate net cash proceeds of EUR 250 million, they are also anticipated to result in a significant financial loss in the coming year.
Read more →-FMS
Feb 20, 2024Christine Peters T +49 160 6066 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@freseniusmedicalcare.com ww
Fresenius Medical Care has published its annual report for the fiscal year 2023 on form 20-F, which is now available on both the company's website and the SEC's website. The company continues to be a leader in renal disease products and services, with approximately 4.1 million patients worldwide undergoing dialysis treatment. Despite its strong market position, the release notes potential risks and uncertainties that could affect future performance, including economic and regulatory factors.
Read more →-FMS
Jan 8, 2024Christine Peters T +49 151 215 275 19 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Ilia K rten T +49 6172 6089 6253 ilia.kuerten@fmc-ag.com www.freseniusmedical
Fresenius Medical Care has announced significant updates regarding its Portfolio Optimization Program as of January 8, 2024. The company has successfully divested several noncore assets, including operations in Argentina and its cardiovascular clinics business in the U.S. These strategic moves are intended to enhance profitability and management focus in 2024. However, the divestitures will negatively affect operating income by an estimated EUR 50 million in the fourth quarter of 2023.
Read more →-FMS
Dec 7, 2023Fresenius Medical Care AG Hof Notification of impending merger pursuant to section 62 (3) sentence 2 of the German Transformation Act Pursuant to section 62 (3) sentence 2 of the German Transformation Act ( Umwandlungsge
Fresenius Medical Care AG has announced its intention to merge with Fresenius Medical Care PensCo GmbH as part of a strategic move under the German Transformation Act. As the sole shareholder, Fresenius Medical Care AG will absorb Fresenius Medical Care PensCo GmbH without requiring approval from a general meeting, although shareholders holding a specific portion of shares can demand one. This merger aims to improve operational efficiency and streamline processes within the company.
Read more →-FMS
Nov 30, 2023Commercial Register B of the Local Court of Hof Company Number HRB 6841 Page 1 of 1 Retrieved on 30 Nov. 2023 at 0920 hours Entry No. a) Name of the company b) Registered office, place of business, business address in Ge
The article discusses the registration details of Fresenius Medical Care AG in the Commercial Register B of the Local Court in Hof, Germany. It includes information about the company's purpose, management structure, and capital. Noteworthy elements include the appointment of various board members and the company's activities in healthcare and pharmaceuticals. The article indicates recent changes to the company's legal structure, specifically its transformation from a partnership into a stock corporation.
Read more →-FMS
Nov 21, 2023AD HOC RELEASE Fresenius Medical Care AG & Co. KGaA: Favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised Bad Homburg
Fresenius Medical Care has settled a legal dispute with the U.S. government through its subsidiary, Fresenius Medical Care Holdings, Inc. The settlement will positively affect the company's revenue and operating income, with an expected impact of approximately EUR 175 million in the fourth quarter of 2023. In light of this resolution, Fresenius has raised its operating income outlook for fiscal year 2023 to a growth of 12-14%. All other elements of the company's financial outlook for 2023 remain unchanged.
Read more →-FMS
Nov 13, 2023Fresenius Medical Care AG & Co. KGaA Hof ISIN: DE0005785802 // WKN: 578580 ISIN: US3580291066 // CUSIP: 358029106 Announcement pursuant to sections 246 para. 4 sentence 1, 249 para. 1 sentence 1 German Stock Corporation
Fresenius Medical Care AG & Co. KGaA announced that a new legal action contesting a resolution from its extraordinary general meeting on July 14, 2023, has been filed. The action relates to the proposed conversion of the company into the legal form of a stock corporation. This lawsuit was registered in the Regional Court of Frankfurt a.M. on November 3, 2023, and is currently under consideration. The legal challenge adds uncertainty to the company's plans for structural changes.
Read more →-FMS
Nov 1, 2023ADHOC RELEASE Fresenius Medical Care AG & Co. KGaA raises outlook for operating income in fiscal year 2023 Bad Homburg
Fresenius Medical Care AG & Co. KGaA has upgraded its outlook for operating income in fiscal year 2023, driven by improvements following successful turnaround measures and operational efficiencies. The company anticipates a low single-digit percentage increase in operating income compared to the previous year. This change is based on the positive earnings development in the first nine months of 2023, with no changes to other elements of the fiscal outlook previously published.
Read more →-FMS
Nov 1, 2023Leif Heussen T +49 6172 608-4030 leif.heussen@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Fresenius Medical Care reported improved operational performance in the first nine months of 2023, leading to a raised earnings outlook for the year. The company highlighted benefits from its FME25 efficiency program and has made strides in portfolio optimization by selling non-core assets. However, the financial results showed a decrease in both operating income and net income compared to the previous year, suggesting challenges remain amidst economic pressures such as inflation and currency exchange impacts.
Read more →-FMS
Jul 14, 2023Steffen Rinas T +49 6172 608-6698 steffen.rinas@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Fresenius Medical Care has successfully converted from a limited partnership into a German stock corporation following shareholder approval at an Extraordinary General Meeting. This restructuring aims to streamline corporate governance, improve decision-making efficiency, and enhance the influence of free float shareholders. The new Supervisory Board, led by Michael Sen, will include diverse representatives and oversee key functions in the company's operations. The complete transition is anticipated to finalize by the end of 2023, while maintaining current governance structures until then.
Read more →-FMS
Jul 10, 2023Steffen Rinas T +49 6172 608-6698 steffen.rinas@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Und
Fresenius Medical Care announced the appointment of Martin Fischer as Chief Financial Officer effective October 1, 2023. Fischer, who previously held key financial positions at Siemens Healthineers, will be responsible for overseeing the Global Finance Organization. His arrival is seen as a strategic move to strengthen the management team during a transformative period for the company. The press release emphasizes the importance of this change in achieving the company's goals in the renal healthcare sector.
Read more →-FMS
Jun 5, 2023Filed by Fresenius Medical Care AG & Co. KGaA (Commission File No. 001-32749), pursuant to Rules 165 and 425 under the Securities Act of 1933, as amended This Exhibit consists of a convenience English translation of Fres
Fresenius Medical Care AG & Co. KGaA has filed a registration statement with the SEC regarding a proposed conversion of its legal form. This includes relevant information for shareholders as they approach an extraordinary general meeting. The firm has issued a translation of its Conversion Report to provide clarity on the implications of this change. However, there are several complexities and risks outlined that could affect shareholders' decisions moving forward.
Read more →-FMS
Jun 2, 2023Content: Statement of earnings page 2 Segment information page 3 Balance sheet page 4 Cash flow page 5 page 6 Key metrics page 7 page 8 - 9 page 10 Outlook 2023 page 11 Disclaimer Copyright by Fresenius Medical Care AG &
Fresenius Medical Care AG released its earnings statement, highlighting challenges such as costs from the FME25 program and impacts from the Ukraine war. The outlook for 2023 suggests low to mid-single-digit revenue growth, but a potential decline in operating income. Special items significantly contribute to variations in financial metrics. Factors like hyperinflation in Turkiye are also affecting the company's financial stability.
Read more →-FMS
May 16, 2023Leif Heussen T +49 6172 608-4030 leif.heussen@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Under
Fresenius Medical Care AG & Co. KGaA (FME) is focusing on a transformational turnaround, as stated by CEO Helen Giza during the Annual General Meeting. Shareholders approved a dividend proposal of 1.12, reflecting a 17 percent decrease from the previous year. The company emphasizes its unique position in global kidney care and aims to enhance patient outcomes through predictive analytics and improved medical algorithms. However, potential risks such as regulatory changes and ongoing economic conditions remain a concern for future performance.
Read more →-FMS
Apr 13, 2023Fresenius Medical Register VIF Proof 3 Annual General Meeting of Fresenius Medical Care AG & Co. KGaA Date
Fresenius Medical Care AG & Co. KGaA will hold its Annual General Meeting on May 16, 2023, to discuss various agenda items including the election of auditors and the approval of fiscal reports. Shareholders are encouraged to exercise their voting rights either in-person or by providing instructions to the Depositary Bank. The company aims to minimize paper usage during the event by providing digital access to relevant materials. Additionally, the meeting will address changes in governance procedures, including provisions for virtual meetings.
Read more →-FMS
Mar 30, 2023INVITATION TO THE ANNUAL GENERAL MEETING T U ES DAY, 1 6 M AY 2023 INVITATION 03 Invitation to the Annual General Meeting I. AGENDA 03 1. Presentation of the annual financial statements and consolidated financial stateme
Fresenius Medical Care AG & Co. KGaA is inviting its shareholders to the Annual General Meeting scheduled for May 16, 2023. The notice details the procedures for participation, including rights related to data privacy under GDPR. Additionally, the company's commitment to providing materials and updates related to the meeting is noted. Shareholders are encouraged to submit their voting instructions by May 5, 2023, for ADR holders specifically through The Bank of New York Mellon.
Read more →-FMS
Feb 23, 2023Martin Kunze T +49 6172 608-2115 martin.kunze@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Fresenius Medical Care has filed its annual report for 2022 with the SEC, underscoring its leadership in renal disease services. The report is accessible on their website, along with a detailed overview of financial figures from the past fiscal year. The company has a global presence, managing numerous dialysis clinics and treating hundreds of thousands of patients. However, it also mentions potential risks that may impact future performance, including regulatory and economic uncertainties.
Read more →-FMS
Feb 21, 2023Martin Kunze T +49 6172 608-2115 martin.kunze@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Under
Fresenius Medical Care is preparing to file a registration statement with the SEC for a proposed conversion. The company reported its FY 2022 financial results, noting overall revenue growth of 10% but a significant decline in operating and net income. CEO Helen Giza emphasized a strategic focus on operational performance and shareholder value creation amidst a challenging environment, with an aim to accelerate transformation initiatives. The company also announced an increase in the savings target for its FME25 transformation program from EUR 500 million to EUR 650 million by 2025.
Read more →-FMS
Feb 9, 2023Ad-hoc announcement according to Art. 17 (1) MAR February 9 th , 2023 Fresenius Medical Care AG & Co. KGaA confirms review of the deconsolidation and a potential change of the legal form into a German stock corporation F
Fresenius Medical Care AG & Co. KGaA has confirmed the review of its deconsolidation and a potential shift to a German stock corporation. This review is part of a structure held by Fresenius SE & Co. KGaA, which owns approximately 32% of the shares. Currently, the necessary decisions regarding this review are still outstanding, leaving the future of the legal form change undetermined.
Read more →-FMS
Dec 6, 2022Ad-hoc announcement according to Art. 17 (1) MAR Media contact Steffen Rinas T +49 6172 608-6698 steffen.rinas@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.c
Ad-hoc announcement according to Art. 17 (1) MAR Media contact Steffen Rinas T +49 6172 608-6698 steffen.rinas@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical
Read more →-FMS
Oct 31, 2022▲ +5.2%on this news
Ad-hoc announcement according to Art. 17 (1) MAR Media contact Matthias Link T +49 6172 609-2872 matthias.link@fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com
Fresenius Medical Care AG & Co. KGaA extends net income target range for financial year 2022 Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company's focused efforts to improve North American Health Care Services operations a
Read more →-FMS
Sep 12, 2022NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fmc-a
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fmc-ag.com Contact for Analysts and Investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care places bonds with a volume of 750
Read more →-FMS
Aug 2, 2022Matthias Link T +49 6172 609-2872 matthias.link@fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Fresenius Medical Care publishes financial results for the second quarter and first half of 2022 in line with preliminary results - Results unchanged compared with preliminary figures published on July 27, 2022 - Business development impacted by unprecedented U.S. labor marke
Read more →-FMS
May 17, 2022FRESENIUS MEDICAL CARE HOLDINGS, INC. AND SUBSIDIARIES Consolidated Financial Statements
AND SUBSIDIARIES Notes to Consolidated Financial Statements (Dollars in thousands, except share data) On March 22, 2022, Fresenius Medical Care announced that the Company has entered into a definitive agreement to create an independent new company with InterWell Health and Cricke
Read more →-FMS
May 3, 2022Ad-hoc announcement according to Art. 17 (1) MAR Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.c
Carla Kriwet succeeds Rice Powell as CEO of the Management Board of Fresenius Medical Care today's meeting the Supervisory Board of Fresenius Medical Care's General Partner unanimously appointed Dr. Carla Kriwet as CEO of the Management Board effective January 1, 2023. Dr. Carl
Read more →-FMS
Mar 30, 2022Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A3MQCP7 // Securities Identification No.: A3MQCP ISIN:
to the Annual General Meeting Medical Care AG & Co. KGaA DE0005785802 // Securities Identification No.: 578580 DE000A3MQCP7 // Securities Identification No.: A3MQCP US3580291066 // CUSIP: 358029106 hereby invite our shareholders to the be held on Thursday, 12 May 2022, at 1
Read more →-FMS
Dec 1, 2021Martin Kunze T +49 6172 609-2115 martin.kunze@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Fresenius Medical Care announces changes to Management Board, reflecting the transformation to the company's new operating model Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced changes to the Ma
Read more →-FMS
Nov 2, 2021Matthias Link T +49 6172 609-2872 matthias.link@fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com November 2, 2021 www.freseniusmedicalcare.com Fresenius Medical Care transforms its o
Read more →-FMS
May 3, 2021Annual General Meeting of Fresenius Medical Care AG & Co. KGaA to be held
Annual General Meeting of Fresenius Medical Care AG & Co. KGaA to be held May 20, 2021 For ADR Holders of Record as of April 12, 2021 Annual General Meeting of Fresenius Medical Care AG & Co. KGaA Date: May 20, 2021 See Instructions On Reverse Side. Please make your marks like
Read more →-FMS
Apr 7, 2021Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN : DE000A3H23E3// Securities Identification No.: A3H23E ISIN:
Invitation to the Annual General Meeting Fresenius Medical Care AG & ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A3H23E3// Securities Identification No.: A3H23E ISIN: US3580291066 // We hereby invite our shareholders to the Annual General Meeting
Read more →-FMS
Sep 10, 2020Matthias Link T +49 6172 609-2872 matthias.link@ fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@ fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care to issue bonds with a volume of 1
Read more →-FMS
Jul 17, 2020Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A254VN2 // Securities Identification No. : A254VN ISIN
Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A254VN2 // Securities Identification No.: A254VN ISIN: US3580291066 // CUSIP: 358029106 We hereby invite our shareholders to t
Read more →-FMS
May 19, 2020NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@ fmc-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Fresenius Medical Care places bonds with a volume of 1.25 billion euros Fresenius Medical Care, the world s largest provider of dialysis pr
Read more →-FMS
May 19, 2020FRESENIUS MEDICAL CARE HOLDINGS, INC. AND SUBSIDIARIES Consolidated Financial Statements December 31,2019 and 2018 (With Independent Auditors' Report Thereon) FRESENIUS MEDICAL CARE HOLDINGS, INC. AND SUBSIDIARIES Table
FRESENIUS MEDICAL CARE HOLDINGS, INC. AND SUBSIDIARIES Consolidated Financial Statements December 31,2019 and 2018 (With Independent Auditors' Report Thereon) FRESENIUS MEDICAL CARE HOLDINGS, INC. AND SUBSIDIARIES Table of Contents Page(s) Independent Auditors' Report 1-2 Consol
Read more →-FMS
Feb 21, 2020Matthias Link T +49 6172 608-2115 matthias.link@fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Press Release Media Contact Matthias Link T +49 6172 608-2115 matthias.link@fmc-ag.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care published form 20-F for the fiscal
Read more →-FMS
Nov 20, 2019NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@frese
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. Fresenius Medical Care places bonds with a volume of 1.75 billion euros Fresenius Medical Care, the world s largest provider of dialysis pr
Read more →-FMS
Aug 27, 2019Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Fresenius Medical Care appoints Helen Giza as Chief Financial Officer Fresenius Medical Care, the world s leading provider of dialysis products and services, has appointed Helen Giza (51) as Chief Financial Officer as of November 1, 2019. She will succeed Mike Brosnan who announ
Read more →-FMS
Jul 10, 2019Fresenius Medical Care Group Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Fresenius Medical Care North America Brad Puffer T +1 781 699-3331 brad.puffer@fmc-na.com
Press Release Media Contact Fresenius Medical Care Group Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Fresenius Medical Care North America Brad Puffer T +1 781 699-3331 brad.puffer@fmc-na.com July 10, 2019 Contact for analysts and investors Dr. Dominik Heger T +
Read more →-FMS
Apr 10, 2019ANNUAL GENERAL MEETING 2 0 1 9 INVITATION TO THE ANNUAL GENERAL MEETING on 16 May 2019, Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A2TSV87
ANNUAL GENERAL MEETING 2 0 1 9 INVITATION TO THE ANNUAL GENERAL MEETING on 16 May 2019, Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A2TSV87 // Securities Identification No.: A2TSV8 ISIN: US3580291
Read more →-FMS
Feb 26, 2019Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Fresenius Medical Care North America Katherine Dobbs T +1 781 699-9039 katherine.dobbs@fmc-na.com Contact for analysts and investo
Fresenius Medical Care completes acquisition of NxStage Medical Fresenius Medical Care, the world s largest provider of dialysis products and services, has successfully completed the acquisition of NxStage Medical, Inc. (NxStage), following approval by antitrust authorities in t
Read more →-FMS
Feb 21, 2019Matthias Link T +49 6172 608-2115 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
Press Release Media Contact Matthias Link T +49 6172 608-2115 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care published form 20-F for the fis
Read more →-FMS
Feb 20, 2019Ad-hoc announcement according Media Contact to Art. 17 (1) MAR Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.c
Ad-hoc announcement according Media Contact to Art. 17 (1) MAR Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Ca
Read more →-FMS
Jan 2, 2019Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com 28
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care awaiting U.S. Federal Trade Com
Read more →-FMS
Dec 6, 2018Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com December 6, 2018 www.freseniusmedicalcare.com Fresenius Medical Care gives early prelimi
Read more →-FMS
Jul 31, 2018Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com 31
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care continues to grow in the second
Read more →-FMS
Jun 11, 2018Fresenius Medical Care Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Fresenius Medical Care North America Katherine Dobbs T +1 781 699-9039 katherine.dobbs@fmc-na.com Contact f
Press Release Media Contact Fresenius Medical Care Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Fresenius Medical Care North America Katherine Dobbs T +1 781 699-9039 katherine.dobbs@fmc-na.com Contact for Analysts and Investors Dr. Dominik Heger T +49
Read more →-FMS
May 3, 2018Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com 3 M
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care remains on track for another re
Read more →-FMS
Apr 19, 2018Fresenius Medical Register VIF Proof 2 Ordinary General Meeting of Fresenius Medical Care AG & Co. KGaA to be held
90366 Fresenius Medical Register VIF Proof 2 FRESENIUS MEDICAL CARE AG & Co. KGaA Instructions to The Bank of New York Mellon, as Depositary Bank (Must be received prior to 5:00 p.m. New York City time on May 4, 2018) The undersigned registered holder of one or more American Depo
Read more →-FMS
Apr 3, 2018Convenience Translation Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A2G9L83 // Securities Identifi
Convenience Translation Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A2G9L83 // Securities Identification No.: A2G9L8 ISIN: US3580291066 // CUSIP: 358029106 We hereby inv
Read more →-FMS
Oct 27, 2017Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Fresenius Medical Care North America Katherine Dobbs T +1 781 699-9039 Katherine.dobbs@fmc-na.com Contact for analysts and investo
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Fresenius Medical Care North America Katherine Dobbs T +1 781 699-9039 Katherine.dobbs@fmc-na.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.h
Read more →-FMS
Aug 1, 2017Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com 1 A
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Fresenius Medical Care delivers another quart
Read more →-FMS
May 12, 2017Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601
Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 May 12, 2017 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com Moody s upgrades Fresenius Medical Care s
Read more →-FMS
Apr 11, 2017Convenience Translation Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA Hof ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A2DA679 // Securities Identification No.: A
Convenience Translation Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A2DA679 // Securities Identification No.: A2DA67 ISIN: US3580291066 // CUSIP: 358029106 We hereby inv
Read more →-FMS
Apr 11, 2017Fresenius Medical Register VIF Proof 3 Ordinary General Meeting of Fresenius Medical Care AG & Co. KGaA to be held
86578 Fresenius Medical Register VIF Proof 3 FRESENIUS MEDICAL CARE AG & Co. KGaA Instructions to The Bank of New York Mellon, as Depositary Bank (Must be received prior to 5:00 p.m. New York City time on April 28, 2017) The undersigned registered holder of one or more American D
Read more →-FMS
Apr 5, 2017Investor News Dr Dominik Heger Head of Investor Relations & Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 Dominik.Heger@fmc-ag.com
Investor News Dr Dominik Heger Head of Investor Relations & Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 Dominik.Heger@fmc-ag.com April 5, 2017 www.freseniusmedicalcare.com Freseniu
Read more →-FMS
Feb 22, 2017Investor News Dr. Dominik Heger Head of Investor Relations & Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 Dominik.Heger@fmc-ag.com
Investor News Dr. Dominik Heger Head of Investor Relations & Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 Dominik.Heger@fmc-ag.com www.freseniusmedicalcare.com February 22, 2017 F
Read more →-FMS
Jan 31, 2017Investor News Dr Dominik Heger Head of Investor Relations & Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 Dominik.Heger@fmc-ag.com
Investor News Dr Dominik Heger Head of Investor Relations & Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 Dominik.Heger@fmc-ag.com www.freseniusmedicalecare.com Fresenius Medical Ca
Read more →-FMS
Jan 13, 2017INVESTOR NEWS CMS TRO Release Update
CMS TRO Release Update Statement of Fresenius Medical Care Regarding Lawsuit Challenging Premium Assistance Regulation: U.S. Court Ruling Granting Temporary Restraining Order Following a hearing on Thursday, the United States District Court of the Eastern District of Texas has
Read more →-FMS
Jan 9, 2017Fresenius Medical Care: Impact of potential regulation change Centers for Medicare and Medicaid Services (CMS) promulgated a new regulation regarding premium assistance programs that help to fund health insurance premium
Fresenius Medical Care: Impact of potential regulation change Centers for Medicare and Medicaid Services (CMS) promulgated a new regulation regarding premium assistance programs that help to fund health insurance premiums for patients with end stage renal disease (ESRD). Many fi
Read more →-FMS
Dec 1, 2016Announcement Fresenius Medical Care will focus on IFRS reporting and discontinue U.S. GAAP financial statements Fresenius Medical Care AG & Co. KGaA will focus its reporting on financial statements in accordance with Int
Announcement Fresenius Medical Care will focus on IFRS reporting and discontinue U.S. GAAP financial statements Fresenius Medical Care AG & Co. KGaA will focus its reporting on financial statements in accordance with International Financial Reporting Standards (IFRS) in Euro cur
Read more →-FMS
Oct 27, 2016INVESTOR NEWS Third quarter 2016
Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE RESULTS FOR THE THIRD QUARTER AND NINE MONTHS 2016 phone: +49 6172 609 2525 fax: +49 6172 609 2301 email: ir@fmc-ag.com Content: Statement of earnings page 9 Segment information page 10 Balance sheet page 11 Cash
Read more →-FMS
Aug 1, 2016INVESTOR NEWS Second quarter/half year 2016
Second quarter/half year 2016 Fresenius Medical Care posts accelerated earnings growth in the 2nd quarter Group revenue +5% (+7% at constant currency) driven by strong results in health care services Considerable net income growth of 22%, supported by lower costs for health ca
Read more →-FMS
Apr 11, 2016Fresenius Medical Register VIF Proof 6 Ordinary General Meeting of Fresenius Medical Care AG & Co. KGaA to be held
84431 Fresenius Medical Register VIF Proof 6 FRESENIUS MEDICAL CARE AG & Co. KGaA Instructions to The Bank of New York Mellon, as Depositary Bank (Must be received prior to 5:00 p.m. New York City time on April 29, 2016) The undersigned registered holder of one or more American D
Read more →-FMS
Apr 1, 2016Convenience Translation Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA Hof ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A169Q13 // Securities Identification No.: A
Convenience Translation Invitation to the Annual General Meeting Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A169Q13 // Securities Identification No.: A169Q1 ISIN: US3580291066 // CUSIP: 358029106 We hereby inv
Read more →-FMS
Mar 11, 2016Joachim Weith Senior Vice President Corporate Communications & Governmental Affairs Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 608-2101 F +49 6172 608-2294 joachim.weit
Press Release Joachim Weith Senior Vice President Corporate Communications & Governmental Affairs Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 608-2101 F +49 6172 608-2294 joachim.weith@fresenius.com www.freseniusmedicalcare.com Fre
Read more →-FMS
Feb 25, 2016Investor News Oliver Maier Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.freseniusmedicalcare.com
Fresenius Medical Care publishes form 20-F for the fiscal year 2015 Bad Homburg, Germany Fresenius Medical Care AG & Co. KGaA ( the company or Fresenius Medical Care ), the world s largest provider of dialysis products and services, today announced that it has filed the annual r
Read more →-FMS
May 20, 2015THIS ANNOUNCEMENT IS BEING FILED AS A MATTER OF RECORD ONLY. IT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY U.S. PERSON, OR IN OR INTO CANADA, AUSTRALIA, SOUTH AFRICA
THIS ANNOUNCEMENT IS BEING FILED AS A MATTER OF RECORD ONLY. IT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY U.S. PERSON, OR IN OR INTO CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN. Notice of adjustment of conversion price of the
Read more →-FMS
May 19, 2015Matthias Link Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2872 F +49 6172 609-2294 matthias.link@fresenius.com www.freseniusmedicalcare.com
Press Release Matthias Link Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2872 F +49 6172 609-2294 matthias.link@fresenius.com www.freseniusmedicalcare.com Fresenius Medical Care confirms growth t
Read more →-FMS
Apr 16, 2015Fresenius Medical Plan VIF Proof 7 Ordinary General Meeting of Fresenius Medical Care AG & Co. KGaA Date
KGaA to be held on May 19, 2015, in respect of the agenda items specified in the accompanying invitation. The Depositary Bank shall not vote or attempt to exercise the voting right attached to the shares or other deposited securities other than in accordance with the specific vot
Read more →-FMS
Apr 7, 2015Convenience Translation Fresenius Medical Care AG & Co. KGaA Hof an der Saale Convening of the ordinary General Meeting ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A13SS29 // Securities Identif
Convenience Translation Fresenius Medical Care AG & Co. KGaA Convening of the ordinary General Meeting ISIN: DE0005785802 // Securities Identification No.: 578580 ISIN: DE000A13SS29 // Securities Identification No.: A13SS2 ISIN: US3580291066 // CUSIP: 358029106 We hereby in
Read more →-FMS
Nov 27, 2014Investor News Oliver Maier Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com
Fresenius Medical Care successfully upsizes and extends the maturity of its credit agreement and also extends the maturity of its accounts receivable facility Bad Homburg, Germany Fresenius Medical Care AG & Co. KGaA (the company or Fresenius Medical Care ; Frankfurt Stock Excha
Read more →-FMS
Nov 13, 2014Oliver Maier Investor News Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com
Oliver Maier Investor News Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com Fresenius Medical Care Announces Agreement to Acquire Cogent Health
Read more →-FMS
May 15, 2014Matthias Link Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2872 F +49 6172 609-2294 matthias.link@fresenius.com www.fmc-ag.com
Press Release Matthias Link Corporate Communications Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2872 F +49 6172 609-2294 matthias.link@fresenius.com www.fmc-ag.com Fresenius Medical Care confirms long-term growth targets - Shar
Read more →-FMS
Apr 14, 2014Fresenius Medical VIF Proof 2 Ordinary General Meeting of Fresenius Medical Care AG & Co. KGaA Date
KGaA to be held on May 15, 2014, in respect of the agenda items specified in the accompanying invitation. The Depositary Bank shall not vote or attempt to exercise the voting right attached to the shares or other deposited securities other than in accordance with the specific vot
Read more →-FMS
Apr 4, 2014Investor News Oliver Maier Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com 04 April 2014 Fre
Investor News Oliver Maier Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com 04 April 2014 Fresenius Medical Care Sets New Long-Term Revenue Ta
Read more →-FMS
Apr 2, 2014Convenience Translation Fresenius Medical Care AG & Co. KGaA Hof an der Saale Convening of the ordinary General Meeting ISIN: DE0005785802 // Securities Identification No. 578580 ISIN: DE000A1YDGF6 // Securities Identifi
Convenience Translation Fresenius Medical Care AG & Co. KGaA Convening of the ordinary General Meeting ISIN: DE0005785802 // Securities Identification No. 578580 ISIN: DE000A1YDGF6 // Securities Identification No. A1YDGF We hereby invite our shareholders to the ordinary Gene
Read more →-FMS
Mar 12, 2014Corporate News Oliver Maier Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com
Corporate News Oliver Maier Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com Fresenius Medical Care Announces Management Board Changes Bad Hom
Read more →-FMS
Feb 25, 2014Fresenius Medical Care Reports Full Year 2013 Results and provides Outlook for 2014 Fresenius Medical Care has achieved its targets for the financial year 2013. Net revenue of Fresenius Medical Care AG & Co. KGaA for the
Fresenius Medical Care Reports Full Year 2013 Results and provides Outlook for 2014 Fresenius Medical Care has achieved its targets for the financial year 2013. Net revenue of Fresenius Medical Care AG & Co. KGaA for the full year 2013 was $14,610 million, up by 6% from the ful
Read more →-FMS
Jul 3, 2013Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN DE0005785802 // Securities Identification No. 578580 (ordinary shares) ISIN DE0005785836 // Securities Identification No. 578583 (preference shares) Notice regar
Fresenius Medical Care AG & Co. KGaA ISIN DE0005785802 // Securities Identification No. 578580 (ordinary shares) ISIN DE0005785836 // Securities Identification No. 578583 (preference shares) regarding the conversion of preference shares into ordinary shares and the admission o
Read more →-FMS
Apr 18, 2013Fresenius Common Proof 7 Ordinary General Meeting of Fresenius Medical care AG & co. KGaA Date
KGaA to be held on May 16, 2013, in respect of the agenda items specified in the accompanying invitation. The depositary Bank shall not vote or attempt to exercise the voting right attached to the shares or other deposited securities other than in accordance with the specific vot
Read more →-FMS
Apr 8, 2013Convenience Translation Fresenius Medical Care AG & Co. KGaA Hof an der Saale Convening of the ordinary General Meeting ISIN: DE0005785802 // Securities Identification No. 578580 ISIN: DE0005785836 // Securities Identifi
Convenience Translation Fresenius Medical Care AG & Co. KGaA Convening of the ordinary General Meeting ISIN: DE0005785802 // Securities Identification No. 578580 ISIN: DE0005785836 // Securities Identification No. 578583 ISIN: DE000A1RFH42 // Securities Identification No. A1
Read more →-FMS
Apr 26, 2012Investor News Fresenius Medical Care AG & Co. KGaA Else-Kr ner-Stra e 1 61352 Bad Homburg / Germany Contact: Oliver Maier T +49 6172 609 2601 F +49 6172 609 2301 Contact North America: Terry Morris T + 1 800 948 2538 F +
Investor News Fresenius Medical Care AG & Co. KGaA Else-Kr ner-Stra e 1 61352 Bad Homburg / Germany Contact: Oliver Maier T +49 6172 609 2601 F +49 6172 609 2301 Contact North America: Terry Morris T + 1 800 948 2538 F + 1 615 345 5605 April 26, 2012 ir@fmc-ag.com Fresenius Medi
Read more →-FMS
Apr 6, 2012Fresenius Medical Care AG & Co. KGaA Shareholder motions All counter motions and proposals for election on specific items on the agenda are to be addressed to Fresenius Medical Care AG & Co. KGaA -Investor Relations- Els
Fresenius Medical Care AG & Co. KGaA Shareholder motions All counter motions and proposals for election on specific items on the agenda are to be addressed to Fresenius Medical Care AG & Co. KGaA -Investor Relations- Else-Kr ner-Stra e 1 61352 Bad Homburg v. d. H. Germany (Telefa
Read more →-FMS
Apr 2, 2012Investor News Fresenius Medical Care AG & Co. KGaA Else-Kr ner-Stra e 1 61352 Bad Homburg / Germany Contact Global: Oliver Maier T +49 6172 609 2601 F +49 6172 609 2301 Contact North America: Terry Morris T + 1 800 948 2
Investor News Fresenius Medical Care AG & Co. KGaA Else-Kr ner-Stra e 1 61352 Bad Homburg / Germany Contact Global: Oliver Maier T +49 6172 609 2601 F +49 6172 609 2301 Contact North America: Terry Morris T + 1 800 948 2538 F + 1 615 345 5605 Media Contact North America: Jon D.
Read more →-FMS
Mar 9, 2012Fresenius Medical Care AG & Co. KGaA Oliver Maier Else-Kr ner-Str.1 Phone: + 49 6172 609 2601 61352 Bad Homburg Fax: + 49 6172 609 2301 Germany www.fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 25
Contact: Fresenius Medical Care AG & Co. KGaA Oliver Maier Else-Kr ner-Str.1 Phone: + 49 6172 609 2601 61352 Bad Homburg Fax: + 49 6172 609 2301 Germany www.fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1 615 345 5605 E-mail: ir@fmc-ag.co
Read more →-FMS
Jan 18, 2012Unassociated Document Contact : Fresenius Medical Care AG & Co. KGaA Oliver Maier Else-Kr ner-Str.1 Phone: + 49 6172 609 2601 61352 Bad Homburg Fax: + 49 6172 609 2301 Germany www.fmc-ag.com North America: Terry L. Morri
Contact : Fresenius Medical Care AG & Co. KGaA Oliver Maier Else-Kr ner-Str.1 Phone: + 49 6172 609 2601 61352 Bad Homburg Fax: + 49 6172 609 2301 Germany www.fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1 615 345 5605 Fresenius Medical Care success
Read more →-FMS
Jan 17, 2012: Fresenius Medical Care AG & Co. KGaA Oliver Maier Else-Kr ner-Str.1 Phone: + 49 6172 609 2601 61352 Bad Homburg Fax: + 49 6172 609 2301 Germany www.fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2
Contact : Fresenius Medical Care AG & Co. KGaA Oliver Maier Else-Kr ner-Str.1 Phone: + 49 6172 609 2601 61352 Bad Homburg Fax: + 49 6172 609 2301 Germany www.fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1 615 345 5605 Fresenius Medical Care announc
Read more →-FMS
May 12, 2011Fresenius Medical Care AG & Co. KGaA Hof an der Saale ISIN: DE0005785802 // WKN 578580 ISIN: DE0005785836 // WKN 578583 ISIN: DE000A1H3200 // WKN A1H320 ISIN: DE000A1H3234 // WKN A1H323 ISIN: US3580291066 ISIN: US3580292
Fresenius Medical Care AG & Co. KGaA ISIN: DE0005785802 // WKN 578580 ISIN: DE0005785836 // WKN 578583 ISIN: DE000A1H3200 // WKN A1H320 ISIN: DE000A1H3234 // WKN A1H323 Notification according to section 30b para. 1 sentence 1 no. 2 German Securities Trading Act regarding a
Read more →-FMS
Apr 11, 2011SUPPLEMENTAL INFORMATION In this letter (1) "FMC AG & Co. KGaA", the "Company", "we" or "our" refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, (2) "Fresenius Medical Care AG" and "FM
SUPPLEMENTAL INFORMATION this letter (1) "FMC AG & Co. KGaA", the "Company", "we" or "our" refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, (2) "Fresenius Medical Care AG" and "FMC-AG" refers to the Company as a German stock corporation be
Read more →-FMS
Jan 27, 2011Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North Ameri
Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax
Read more →-FMS
Jan 14, 2011PRESS - RELEASE Fresenius Medical Care North America Initiates Voluntary Recall of CombiSet True Flow Series Hemodialysis Blood Tubing Set with Priming Set and Transducer Protectors for use with the Blood Volume Monitor
Fresenius Medical Care North America Initiates Voluntary Recall of CombiSet True Flow Series Hemodialysis Blood Tubing Set with Priming Set and Transducer Protectors for use with the Blood Volume Monitor FOR IMMEDIATE RELEASE - January 14, 2011 - Waltham, MA - Fresenius Medical
Read more →-FMS
Nov 2, 2010Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North Ameri
Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1
Read more →-FMS
Oct 1, 2010Unassociated Document Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@
Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: +
Read more →-FMS
Aug 26, 2010Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North Ame
Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Germany Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 F
Read more →-FMS
Apr 13, 2010SUPPLEMENTAL INFORMATION As a foreign private issuer under the rules and regulations of the U.S. Securities and Exchange Commission, Fresenius Medical Care AG & Co. KGaA (hereinafter also referred to as FMC AG & Co. KGaA
SUPPLEMENTAL INFORMATION As a foreign private issuer under the rules and regulations of the U.S. Securities and Exchange Commission, Fresenius Medical Care AG & Co. KGaA (hereinafter also referred to as FMC AG & Co. KGaA, the "Company", "we" or "our") is not presently subject to
Read more →-FMS
Mar 26, 2010Convenience Translation Fresenius Medical Care AG & Co. KGaA Hof an der Saale Invitation to ordinary General Meeting ISIN: DE 0005785802 // Securities Identification No. 578 580 ISIN: DE 0005785836 // Securities Identifi
Convenience Translation Fresenius Medical Care AG & Co. KGaA Invitation to ordinary General Meeting ISIN: DE 0005785802 // Securities Identification No. 578 580 ISIN: DE 0005785836 // Securities Identification No. 578 583 ISIN: DE 000A1CSBH7// Securities Identification No.
Read more →-FMS
Feb 25, 2010Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te
Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1 615
Read more →-FMS
Dec 9, 2009Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te
Fresenius Medical Care AG & Co. KGaA Investor News Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1 6
Read more →-FMS
Aug 4, 2009Fresenius Medical Care AG & Co. KGaA Investor Relations Investor News Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te
Fresenius Medical Care AG & Co. KGaA Investor Relations Investor News Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1 6
Read more →-FMS
Mar 24, 2009Fresenius Medical Care AG & Co. KGaA Hof an der Saale Invitation to ordinary General Meeting ISIN: DE 0005785802 // Securities Identification No. 578 580 ISIN: DE 0005785836 // Securities Identification No. 578 583 ISIN:
Fresenius Medical Care AG & Co. KGaA Invitation to ordinary General Meeting ISIN: DE 0005785802 // Securities Identification No. 578 580 ISIN: DE 0005785836 // Securities Identification No. 578 583 ISIN: DE 000A0LR9S4 // Securities Identification No. A0LR9S ISIN: US 35802910
Read more →-FMS
Apr 18, 2008SUPPLEMENTAL INFORMATION As a foreign private issuer under the rules and regulations of the U.S. Securities and Exchange Commission, Fresenius Medical Care AG & Co, KGaA (hereinafter also referred to as FMC AG & Co. KGaA
SUPPLEMENTAL INFORMATION As a foreign private issuer under the rules and regulations of the U.S. Securities and Exchange Commission, Fresenius Medical Care AG & Co, KGaA (hereinafter also referred to as FMC AG & Co. KGaA, the Company , we or our ) is not presently subject to
Read more →-FMS
Apr 2, 2007Fresenius Medical Care AG & Co.
Fresenius Medical Care AG & Co. KGaA Invitation to ordinary General Meeting ISIN: DE 0005785802 // Securities Identification No. 578 580 ISIN: DE 0005785836 // Securities Identification No. 578 583 ISIN: DE 000A0LR9R6 // Securities Identification No. A0LR9R ISIN: US 35802910
Read more →-FMS
Aug 3, 2006Fresenius Medical Care AG & Co. KGaA Investor Relations Investor News Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: He
Fresenius Medical Care AG & Co. KGaA Investor Relations Investor News Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Heinz Schmidt Phone: + 1 781 402 9000
Read more →-FMS
Jun 2, 2006Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail : ir@fmc-ag.com North America: H
Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail : ir@fmc-ag.com North America: Heinz Schmidt Phone: + 1 781 402 9000 Ext.:
Read more →-FMS
May 3, 2006Investor News Fresenius Medical Care AG Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: 49 6172 609 2601 Fax: 49 6172 609 2301 E-mail : ir@fmc-ag.com North America: Heinz S
Investor News Fresenius Medical Care AG Co. KGaA Investor Relations Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: 49 6172 609 2601 Fax: 49 6172 609 2301 E-mail : ir@fmc-ag.com North America: Heinz Schmidt Phone: 1 781 402 9000 Ext
Read more →-FMS
Apr 7, 2006GRAPHIC OMITTED] Fresenius Medical Care Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kroner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier ------------ Phone: + 49 6172 609 2601 Fax: + 49
Fresenius Medical Care Fresenius Medical Care AG & Co. KGaA Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com Phone: + 1 781 402 9000 Fax: + 1 781 402 9741 E-mail: ir@fmc-ag.com Internet: http://www.fmc-ag.com --------------------- Fresenius Medica
Read more →-FMS
Apr 7, 2006Fresenius Medical Care AG Co. KGaA Hof an der Saale Invitation to ordinary General Meeting ISIN: DE 0005785802 // Securities Identification No. 578 580 ISIN: DE 0005785836 // Securities Identification No. 578 583 ISIN: D
Fresenius Medical Care AG Co. KGaA Invitation to ordinary General Meeting ISIN: DE 0005785802 // Securities Identification No. 578 580 ISIN: DE 0005785836 // Securities Identification No. 578 583 ISIN: DE 000A0JCZP0 // Securities Identification No. A0JCZP ISIN: US 3580291066
Read more →-FMS
Mar 15, 2006GRAPHIC OMITTED] FRESENIUS MEDICAL CARE PRESS RELEASE Contact: Contact: Oliver Maier Heinz Schmidt Sr V.P. Investor Relations & Communications Vice President Investor Relations Phone: + 49 6172 609 2601 Phone: + 1 781 40
FRESENIUS MEDICAL CARE Oliver Maier Heinz Schmidt Sr V.P. Investor Relations & Communications Vice President Investor Relations Phone: + 49 6172 609 2601 Phone: + 1 781 402 4518 Fax + 49 6172 609 2301 Fax: + 1 781 402 9741 E-mail: ir@fmc-ag.com E-mail: ir@fmc-ag.com Interne
Read more →-FMS
Feb 28, 2006GRAPHIC OMITTED] FRESENIUS MEDICAL CARE Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kroner-Str. 1 D-61352 Bad Homburg Contact: Contact: Oliver Maier Heinz Schmidt Sr V.P. Investor Relations
FRESENIUS MEDICAL CARE Investor News Fresenius Medical Care AG & Co. KGaA Oliver Maier Heinz Schmidt Sr V.P. Investor Relations & Communications Vice President Investor Relations Phone: + 49 6172 609 2601 Phone: + 1 781 402 4518 Fax + 49 6172 609 2301 Fax: + 1 781 402 9741
Read more →-FMS
Feb 22, 2006GRAPHIC OMITTED] FRESENIUS MEDICAL CARE Investor News Fresenius Medical Care AG & Co. KGaA Investor Relations Else-Kroner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier ------------ Phone: + 49 6172 609 2601 Fax + 49 6
FRESENIUS MEDICAL CARE Investor News Fresenius Medical Care AG & Co. KGaA Phone: + 49 6172 609 2601 Fax + 49 6172 609 2301 E-mail: ir@fmc-ag.com Phone: + 1 781 402 9000 Fax: + 1 781 402 9741 E-mail: ir@fmc-ag.com Internet: http://www.fmc-ag.com --------------------- Fre
Read more →Competitive Position
How FMS ranks across every disease it competes inCompetitive Position is a premium feature
See how FMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial